Skip to content
DataLookout
Menu

NCT06690398

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 35 → 39 locations
  2. Notable Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 3 words
  3. Minor Site details revised at 2 of 35 sitesv8
  4. Minor Site details revised at 2 of 35 sitesv7
  5. Minor Study sites: 34 to 35v6
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Enrollment target: 174 to 160
    • Study sites: 37 to 34
    • Primary completion date: Mar 2027 to Jun 21, 2027
    • Study completion date: Apr 2027 to Jul 19, 2027
    v5
  2. Minor Study sites: 33 to 37v4
  3. Minor Start date changed from estimate of Nov 2024 to Nov 22, 2024v3
  4. Notable Eligibility criteria expanded, about 3 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Aberrant Behavior Checklist - Irritability (ABC-I)
Timeframe: Week 6

Secondary (1)

Clinical Global Impression-Severity (CGI-S)

Arms and interventions

Lumateperone high doseExperimental

Lumateperone 42 mg for patients ages 13-17 years old

Lumateperone low doseExperimental

Lumateperone 21 mg for patients ages 13-17 years old

PlaceboPlacebo comparator

Placebo

Drugs: Lumateperone high dose, Lumateperone low dose, Placebo

Sites

39 sites in 2 countries

United States 35, Serbia 4